Abstract
Background: Cancer and multiple non-cancer conditions are considered by the Centers for Disease Control and Prevention (CDC) as high risk conditions in the COVID-19 emergency. Professional societies have recommended changes in cancer service provision to minimize COVID-19 risks to cancer patients and health care workers. However, we do not know the extent to which cancer patients, in whom multi-morbidity is common, may be at higher overall risk of mortality as a net result of multiple factors including COVID-19 infection, changes in health services, and socioeconomic factors. Methods: We report multi-center, weekly cancer diagnostic referrals and chemotherapy treatments until April 2020 in England and Northern Ireland. We analyzed population-based health records from 3,862,012 adults in England to estimate 1-year mortality in 24 cancer sites and 15 non-cancer comorbidity clusters (40 conditions) recognized by CDC as high-risk. We estimated overall (direct and indirect) effects of COVID-19 emergency on mortality under different Relative Impact of the Emergency (RIE) and different Proportions of the population Affected by the Emergency (PAE). We applied the same model to the US, using Surveillance, Epidemiology, and End Results (SEER) program data. Results: Weekly data until April 2020 demonstrate significant falls in admissions for chemotherapy (45-66% reduction) and urgent referrals for early cancer diagnosis (70-89% reduction), compared to pre-emergency levels. Under conservative assumptions of the emergency affecting only people with newly diagnosed cancer (incident cases) at COVID-19 PAE of 40%, and an RIE of 1.5, the model estimated 6,270 excess deaths at 1 year in England and 33,890 excess deaths in the US. In England, the proportion of patients with incident cancer with ≥1 comorbidity was 65.2%. The number of comorbidities was strongly associated with cancer mortality risk. Across a range of model assumptions, and across incident and prevalent cancer cases, 78% of excess deaths occur in cancer patients with ≥1 comorbidity. Conclusion: We provide the first estimates of potential excess mortality among people with cancer and multimorbidity due to the COVID-19 emergency and demonstrate dramatic changes in cancer services. To better inform prioritization of cancer care and guide policy change, there is an urgent need for weekly data on cause-specific excess mortality, cancer diagnosis and treatment provision and better intelligence on the use of effective treatments for comorbidities.
Competing Interest Statement
ML has received honoraria from Pfizer, EMD Serono and Roche for presentations unrelated to this research. ML has received an unrestricted educational grant from Pfizer for research unrelated to the research presented in this paper. MDF has received research funding from AstraZeneca, Boehringer Ingelheim, Merck and MSD and honoraria from Achilles, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Meyers Squibb, Celgene, Guardant Health, Merck, MSD, Nanobiotix, Novartis, Pharmamar, Roche and Takeda for advisory roles or presentations unrelated to this research. GRF receives funding from companies that manufacture drugs for hepatitis C virus (AbbVie, Gilead, MSD) and consult for GSK and Arbutus in areas unrelated to this research.
Clinical Trial
Not applicable.
Funding Statement
We acknowledge Health Data Research UK (HDR UK) support for the HDR UK substantive sites involved in this research (HDR London, HDR Wales and Northern Ireland) and DATA-CAN. DATA-CAN is part of the Digital Innovation Hub Programme, delivered by HDR UK and funded by UK Research and Innovation through the governments Industrial Strategy Challenge Fund (ISCF). AGL is supported by funding from the Wellcome Trust, National Institute for Health Research (NIHR) University College London Hospitals and NIHR Great Ormond Street Hospital Biomedical Research Centers. AB is supported by research funding from NIHR, British Medical Association, Astra-Zeneca and UK Research and Innovation. KPJ is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre. CD is funded by UCLPartners. HH is an NIHR Senior Investigator and is funded by the NIHR University College London Hospitals Biomedical Research Centre, supported by Health Data Research UK (grant No. LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, Wellcome Trust, The BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted (20_074R2) by the MHRA (UK) Independent Scientific Advisory Committee of the Clinical Practice Research Data Link under Section 251 (NHS Social Care Act 2006).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available in the manuscript.
